Journal of Pediatric Neurology 2023; 21(02): 095-100
DOI: 10.1055/s-0042-1750762
Case Report

Profile and Outcome of Children with Opsoclonus Myoclonus Ataxia: A Tertiary Care Hospital Experience from India

1   Department of Pediatrics, Manipal Hospital, Bengaluru, Karnataka, India
,
Ayesha Thanvi
1   Department of Pediatrics, Manipal Hospital, Bengaluru, Karnataka, India
,
Sameeta M. Prabhu
1   Department of Pediatrics, Manipal Hospital, Bengaluru, Karnataka, India
› Author Affiliations

Abstract

Opsoclonus myoclonus ataxia syndrome (OMAS) is a rare but treatable, often paraneoplastic neuroimmunologic condition. This is a retrospective chart review of 8 patients diagnosed in the past 11 years at a tertiary care hospital. The mean age of children with OMAS was 21.2 ± 8 months. There was a female preponderance (62.5%). Median symptom duration was 24.5 days (interquartile range [IQR] 12.7; 97.5). All patients had ataxia and irritability; 6 had opsoclonus.

An underlying neurogenic tumor was identified in 87.5% (⅞) of the patients by computed tomography (CT)/magnetic resonance imaging. Neuroblastoma was detected in ⅘ with normal 24-hour urinary vanillylmandelic acid and 2 had negative metaiodobenzylguanidine scan.

All patients received adrenocorticotropic hormone/steroids for a median of 9.5 months (IQR 5.3; 13.5) with clonazepam. Five received intravenous immunoglobulin (IVIG), including repeated cycles in ⅘. Two received rituximab. One child with relapsing-remitting course received pulse dexamethasone and cyclophosphamide, resulting in improvement. Clonazepam restored ambulation in one with delayed diagnosis and failure of response to steroids. Six patients underwent tumor resection and four needed chemotherapies.

Median follow-up was 15 months (IQR 10.7; 23.2). Mean OMAS-severity scale reduced from 10 to 1.4 in the IVIG group and 10.6 to 5.3 in those who did not receive IVIG. Cognitive delay and behavioral issues were seen in 100% treated with steroids only; 50 and 25%, respectively, treated with multimodal immunotherapy. Five had relapses, one with tumor recurrence.

Thorax and abdomen CT scan was found to be a sensitive tool for tumor detection. Better motor and cognitive behavioral outcome were noted in patients who received adjunctive IVIG.

Future studies on optimum investigation and treatment protocol in various resource settings are needed.

Note

This study was earlier presented at the Banglore Pedicon 2019 (poster), Neuropedicon 2021 (poster).




Publication History

Received: 12 March 2022

Accepted: 19 May 2022

Article published online:
11 July 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Kinsbourne M. Myoclonic encephalopathy of infants. J Neurol Neurosurg Psychiatry 1962; 25 (03) 271-276
  • 2 Matthay KK, Blaes F, Hero B. et al. Opsoclonus myoclonus syndrome in neuroblastoma a report from a workshop on the dancing eyes syndrome at the advances in neuroblastoma meeting in Genoa, Italy, 2004. Cancer Lett 2005; 228 (1-2): 275-282
  • 3 Rossor T, Yeh EA, Khakoo Y. et al; OMS Study Group. Diagnosis and management of opsoclonus-myoclonus-ataxia syndrome in children: an international perspective. Neurol Neuroimmunol Neuroinflamm 2022; 9 (03) e1153
  • 4 Hasegawa S, Matsushige T, Kajimoto M. et al; Japanese Society for Pediatric Immune-mediated Brain Diseases. A nationwide survey of opsoclonus-myoclonus syndrome in Japanese children. Brain Dev 2015; 37 (07) 656-660
  • 5 Pranzatelli MR, Tate ED, McGee NR. Demographic, clinical, and immunologic features of 389 children with opsoclonus-myoclonus syndrome: a cross-sectional study. Front Neurol 2017; 8: 468
  • 6 Huddar A, Bindu PS, Nagappa M. et al. Pediatric opsoclonus-myoclonus-ataxia syndrome: experience from a tertiary care university hospital. Neurol India 2018; 66 (05) 1332-1337
  • 7 Muthusamy K, Thomas M, Yoganathan S, Sudhakar SV. Clinical profile, prognostic indicators, and therapeutic outcomes of pediatric opsoclonus-myoclonus-ataxia syndrome: a single-center experience from South India. Ann Indian Acad Neurol 2019; 22 (03) 295-301
  • 8 de Alarcon PA, Matthay KK, London WB. et al. Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. Lancet Child Adolesc Health 2018; 2 (01) 25-34
  • 9 Pranzatelli MR, Tate ED, Travelstead AL. et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 2006; 28 (09) 585-593
  • 10 Brunklaus A, Pohl K, Zuberi SM, de Sousa C. Outcome and prognostic features in opsoclonus-myoclonus syndrome from infancy to adult life. Pediatrics 2011; 128 (02) e388-e394
  • 11 Singhi P, Sahu JK, Sarkar J, Bansal D. Clinical profile and outcome of children with opsoclonus-myoclonus syndrome. J Child Neurol 2014; 29 (01) 58-61
  • 12 Meena JP, Seth R, Chakrabarty B, Gulati S, Agrawala S, Naranje P. Neuroblastoma presenting as opsoclonus-myoclonus: a series of six cases and review of literature. J Pediatr Neurosci 2016; 11 (04) 373-377
  • 13 De Grandis E, Parodi S, Conte M. et al. Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome. Neuropediatrics 2009; 40 (03) 103-111
  • 14 Anand S, Agarwala S, Jain V. et al. Neuroblastoma with opsoclonus-myoclonus-ataxia syndrome: role of chemotherapy in the management: experience from a tertiary care center in a resource-limited setting. J Pediatr Hematol Oncol 2021; 43 (07) e924-e929
  • 15 Pang KK, de Sousa C, Lang B, Pike MG. A prospective study of the presentation and management of dancing eye syndrome/opsoclonus-myoclonus syndrome in the United Kingdom. Eur J Paediatr Neurol 2010; 14 (02) 156-161
  • 16 Pranzatelli MR, Tate ED. Trends and tenets in relapsing and progressive opsoclonus-myoclonus syndrome. Brain Dev 2016; 38 (05) 439-448
  • 17 Wilken B, Baumann M, Bien CG, Hero B, Rostasy K, Hanefeld F. Chronic relapsing opsoclonus-myoclonus syndrome: combination of cyclophosphamide and dexamethasone pulses. Eur J Paediatr Neurol 2008; 12 (01) 51-55
  • 18 Paliwal VK, Chandra S, Verma R, Kalita J, Misra UK. Clonazepam responsive opsoclonus myoclonus syndrome: additional evidence in favour of fastigial nucleus disinhibition hypothesis?. J Neural Transm (Vienna) 2010; 117 (05) 613-615
  • 19 Bartos A. Effective high-dose clonazepam treatment in two patients with opsoclonus and myoclonus: GABAergic hypothesis. Eur Neurol 2006; 56 (04) 240-242
  • 20 Garg RK, Kar AM, Dixit V. Opsoclonus–myoclonus syndrome in an adult: a case report and response to clonazepam. Indian J Ophthalmol 1996; 44 (02) 101-102